Results 81 to 90 of about 73,942 (286)

Problems of pain and quality of life in rheumatoid arthritis: focus on baricitinib

Научно-практическая ревматология, 2020
Modern therapy for rheumatoid arthritis (RA) allows not only to reduce the activity of immune-mediated inflammation and slow down the progression of the disease, but also to quickly eliminate the main symptoms that cause the most concern to patients ...
A. E. Karateev
doaj   +1 more source

Evaluating Janus Kinase Inhibitors as Target Therapies in Atopic Dermatitis

, 2022
Atopic dermatitis (AD) pathogenesis involves cytokines that harness the Janus kinase/signal transducer and activator of the transcription (JAK-STAT) signaling cascade.1 For this reason, Janus Kinase inhibitors (JAKi) are target therapies in AD.1 This ...
Reno, Hunter
core  

Granuloma annulare skin profile shows activation of T-helper cell type 1, T-helper cell type 2, and Janus kinase pathways

, 2020
Background: Granuloma annulare (GA) is an inflammatory skin disorder. Localized GA is often self-resolving, but generalized GA is often recalcitrant to treatments. There are no targeted treatments for GA, largely due to lack of mechanistic understanding.
Zhang N., Sanz-Cabanillas J. L., Min M. S., Lebwohl M., Pavel A. B., Wu J., Renert-Yuval Y., Guttman-Yassky E., He H., Del Duca E.   +9 more
core   +1 more source

First‐in‐human, phase I, randomized, safety, pharmacokinetic, food‐effect and pharmacodynamic study of a tyrosine kinase 2/Janus kinase 1 inhibitor, SDC‐1801

British Journal of Clinical Pharmacology, EarlyView.
Aim The purpose of this study is to evaluate safety, tolerability, pharmacokinetics (PK), food‐effect (FE) and pharmacodynamics (PD) of an oral tyrosine kinase‐2 (TYK2)/Janus kinase‐1 (JAK1) inhibitor, SDC‐1801, in healthy adult participants. Methods This first‐in‐human study randomized 95 male and female participants.
Chris Brearley, Sam Francis, John Reader, Judi Proctor   +3 more
wiley   +1 more source

Molecular Dynamics Simulation Analysis of JAK1 Initial Activation: Phosphorylation-Induced Conformational Dynamics and Domain Interactions

Life
Janus kinase is critical for cytokine-mediated signaling, and its hyperactivation due to mutations drives various diseases. The activation of Janus kinase 1 (JAK1) involves a conformational transition from a closed to an open state, but the underlying ...
Xinyu Peng, Kefu Liu, Guodong Chen, Shengjie Sun   +3 more
doaj   +1 more source

What Makes an “Ideal” Cell Line for Recombinant Adeno‐Associated Virus Production?

Biotechnology and Bioengineering, EarlyView.
Several host cell types have been used to produce rAAVs to date. Cell line‐specific traits that are beneficial in the context of rAAV manufacturing are reviewed here, with the goal of developing a consensus on the ‘ideal’ characteristics that an rAAV production host should possess (created with Biorender.com).
James Conheady, Nicholas Donohue, Alexandra Bogdanovic, Sharon Davin, Brian Glennon, Niall Barron, C. Mark Smales   +6 more
wiley   +1 more source

Biomaterials for modulating cellular responses of endogenous tendon stem/progenitor cells: A promising avenue for tendon regeneration

BMEMat, EarlyView.
This review comprehensively summarizes emerging biomaterial‐based strategies and underlying mechanisms for modulating endogenous tendon stem/progenitor cells (TSPCs). It offers the most recent insights into TSPC physiology and potential applications of tissue engineering and regenerative medicine in tendons.
Zeyu Zhu, Renwang Sheng, Mumin Cao, Ludvig J. Backman, Yucheng Gao, Hao Wang, Cheng Zhang, Jialin Chen, Wei Zhang, Yunfeng Rui   +9 more
wiley   +1 more source

Racial and ethnic diversity in Janus kinase inhibitor alopecia areata clinical trials

, 2023
Alopecia areata (AA) is a chronic autoimmune disease that causes non-scarring alopecia. In June 2022, baricitinib, a Janus kinase (JAK) inhibitor, became the first Federal Drug Administration (FDA) approved medication for adult patients with severe AA ...
Ezemma, O (via Mendeley Data)
core   +1 more source

From Inflammatory Bowel Disease to Cancer: Gut Microbiota–Immune Microenvironment Crosstalk and Natural Product‐Based Therapeutic Opportunities

Cancer Nexus, EarlyView.
ABSTRACT Inflammatory bowel disease (IBD), primarily Crohn's disease and ulcerative colitis, is a chronic relapsing inflammatory disorder of the gastrointestinal tract and an important risk factor for IBD‐associated cancer. Increasing evidence suggests that gut microbiota dysbiosis, epithelial barrier dysfunction, and immune microenvironment remodeling
Xue Zhang, Chongchong Gao, Rui Jiang, Zijian Wu, Jian Bai   +4 more
wiley   +1 more source

CAQ Corner: Basic concepts of transplant immunology

, 2022
Liver Transplantation, EarlyView.
Amanda Cheung, Josh Levitsky
wiley   +1 more source